Amgen Inc. is at a crossroads as sales of multiple legacy products face generics, biosimilars and other competitors, while new revenue generators haven't grown enough to fill blockbuster sales gaps. Executive vice president of global commercial operations Murdo Gordon joined the company last year and is tasked with keeping Repatha, Aimovig and Evenity on the path to growth, while preventing sales of Neulasta, Enbrel and Sensipar from traveling too far south.
Gordon is likely to face the bulk of analysts' questions during the company's 30 July call to discuss second quarter 2019 earnings, but Scrip spoke with him during a visit to Amgen's headquarters after its first quarter
Amgen's Biosimilars Business
Since Scrip spoke with Murdo Gordon, Amgen has claimed a victory in the biosimilar space, becoming the first company – with its partner Allergan PLC – to launch biosimilars in the US for Roche's blockbuster cancer therapies Avastin and Herceptin, named Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns), respectively. (Also see "US Market For Therapeutic Cancer Biosimilars Will Be Tested By Mvasi, Kanjinti Launches" - Scrip, 19 July, 2019.)
These products, which represent the first oncology biosimilars for the US market, launched slightly earlier than expected. Amgen has been particularly bullish about its biosimilar portfolio compared with others companies that have launched biosimilars in the US and faced challenges turning these into significant revenue producers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
